CAL
REGN icon

Capital Advisors Ltd’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Advisors Ltd’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Sell
15
-10
-40% -$6.81K ﹤0.01% 880
2026
Q1 		$19K Buy
25
+10
+67% +$7.66K ﹤0.01% 685
2025
Q4 		$12K Sell
15
-2
-12% -$1.36K ﹤0.01% 773
2025
Q3 		$10K Buy
+17
New +$9.61K ﹤0.01% 809
2025
Q2 		– Sell
-16
Closed -$10K – 1586
2025
Q1 		$10K Buy
16
+5
+45% +$3.44K ﹤0.01% 776
2024
Q4 		$8K Sell
11
-2
-15% -$1.68K ﹤0.01% 838
2024
Q3 		$14K Hold
13
– – ﹤0.01% 709
2024
Q2 		$14K Hold
13
– – ﹤0.01% 678
2024
Q1 		$13K Buy
13
+2
+18% +$1.9K ﹤0.01% 667
2023
Q4 		$10K Hold
11
– – ﹤0.01% 694
2023
Q3 		$9K Hold
11
– – ﹤0.01% 710
2023
Q2 		$8K Sell
11
-1
-8% -$771 ﹤0.01% 739
2023
Q1 		$10K Buy
12
+1
+9% +$754 ﹤0.01% 563
2022
Q4 		$8K Hold
11
– – ﹤0.01% 590
2022
Q3 		$8K Buy
+11
New +$6.92K ﹤0.01% 574
2022
Q2 		– Sell
-2
Closed -$1K – 1266
2022
Q1 		$1K Buy
+2
New +$1.26K ﹤0.01% 784

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital Advisors Ltd's REGN Position: Q2 2026 in Review

Capital Advisors Ltd reduced its Regeneron Pharmaceuticals (REGN) stake by 40% in Q2 2026, selling an estimated $6.81K and leaving 15 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Capital Advisors Ltd first reported a position in REGN in Q1 2022 and has held it in 16 quarters since. The position peaked at $19K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital Advisors Ltd held 15 shares of Regeneron Pharmaceuticals worth $9K as of Q2 2026.
  • Capital Advisors Ltd sold 10 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.81K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #880 holding.
  • Capital Advisors Ltd first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Capital Advisors Ltd's Regeneron Pharmaceuticals position peaked at $19K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.